Latest Corcept Therapeutics Stories

2014-05-08 12:25:31

Feature spotlights both drug companies' digital marketing initiatives for getting their name out to patient and physician community; winning companies to be honored at CBI's iPharma 2014 summit NEW YORK, May 8, 2014 /PRNewswire/ -- PHARMACEUTICAL EXECUTIVE magazine's May cover story http://www.pharmexec.com/pharmexec/Top+Feature/2014-Brand-of-the-Year/ArticleStandard/Article/detail/842582 and the interactive eBook "iDigital Marketing Winning Brands," available for free in the iTunes...

2014-05-07 08:29:17

Winners include Teva's Coxapone, a specialty drug for the treatment of chronic disease, and Corcepts' KORLYM, an orphan drug for a rare condition NEW YORK, May 7, 2014 /PRNewswire/ -- PHARMACEUTICAL EXECUTIVE magazine's June cover story and the magazine's "iDigital Marketing Winning Brands," an interactive eBook available for free in the iTunes Store https://itunes.apple.com/us/app/pharma-sci/id568221918?mt=8 features the publication's eighth annual Brand of The Year awards. This...

2008-09-04 12:00:32

US-based pharmaceutical company Corcept Therapeutics has announced that Eli Lilly and Company has agreed to fund studies to test the effectiveness of Corcept's selective GRII receptor antagonist, CORT 108297, in rat models of olanzapine induced weight gain. Corcept has previously published the results of studies in rats that demonstrated that CORLUX, a potent GRII (cortisol) receptor antagonist, both reduced the weight gain associated with the ongoing use of olanzapine and mitigated the...

Word of the Day
  • Boughs or branches.
  • Warbling of birds in trees.